With the FDA passing the Modernization Act 2.0 in December 2022 and the European Parliament adopting a resolution to phase out animal testing in September 2022, the need for the shift is more urgent than ever.
DART enables you to predict and manage safety concerns such as neurovirulence, neurotoxicity, and sterility in the workflow during the R&D, clinical trials, and production phases without involving animal experimentation.
Higher relevance to human physiology
No animal experimentation or biopsies
Cost effective modern approach
Enhanced prediction accuracy with ML models
Seamless integration into the company’s existing Quality Check workflow
Reduction in testing time drastically
DART uses advanced technologies that apply deep-learning neural network algorithms to generate highly accurate human-relevant scientific data.
An in-vitro platform that uses a human micro physiological system created from an ethically sourced biobank.
A digital workstation solution to predict safety concerns by comparing with benchmark patterns derived through segmentation model training to provide accurate predictions.
Prediction of neurovirulence and sterility in the vaccine production workflow
Prediction of neurovirulence in viral vaccine development process
Prediction of antivenom potency and effectiveness
Prediction of CAR-T cell therapy-induced neurotoxicity